Almirall S.A. Market Cap ($2.63 Billion)
Market Cap & Net Worth: Almirall S.A. (ALM)
Almirall S.A. market cap. Almirall S.A. (MC:ALM) has a market capitalization of $2.63 Billion (€2.25 Billion) as of October 31, 2026. Listed on the MC stock exchange, this Spain-based company holds position #5134 globally and #45 in its home market, demonstrating a 1.35% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Almirall S.A.'s stock price €10.52 by its total outstanding shares 214577056 (214.58 Million).
Almirall S.A. Market Cap History (2015–2026)
Almirall S.A. market cap history from 2015 to 2026. Data shows change from $4.15 Billion to $2.64 Billion (-3.06% CAGR). Check Almirall S.A. share price for real-time trading data and today's change.
Almirall S.A. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Almirall S.A.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Also see ALM cash flow conversion for how efficiently the company converts equity into cash flow.
Latest Price to Sales (P/S) Ratio
2.10x
Almirall S.A.'s market cap is 2.10 times its annual revenue
Latest Price to Earnings (P/E) Ratio
203.59x
Almirall S.A.'s market cap is 203.59 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $4.15 Billion | $689.23 Million | $131.83 Million | 6.02x | 31.49x |
| 2016 | $3.33 Billion | $764.36 Million | $75.48 Million | 4.35x | 44.06x |
| 2017 | $1.90 Billion | $639.38 Million | -$303.96 Million | 2.97x | N/A |
| 2018 | $3.08 Billion | $756.93 Million | $77.67 Million | 4.07x | 39.70x |
| 2019 | $3.41 Billion | $855.34 Million | $105.91 Million | 3.99x | 32.21x |
| 2020 | $2.59 Billion | $1.61 Billion | $74.28 Million | 1.60x | 34.82x |
| 2021 | $2.70 Billion | $827.20 Million | -$40.86 Million | 3.27x | N/A |
| 2022 | $2.19 Billion | $863.25 Million | $4.28 Million | 2.54x | 512.73x |
| 2023 | $2.08 Billion | $894.52 Million | -$38.47 Million | 2.33x | N/A |
| 2024 | $2.07 Billion | $985.72 Million | $10.15 Million | 2.10x | 203.59x |
Competitor Companies of ALM by Market Capitalization
Companies near Almirall S.A. in the global market cap rankings as of October 31, 2026. See Almirall S.A. net asset quality index to understand what proportion of total assets are financed by equity.
Key companies related to Almirall S.A. by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #515 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #536 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #600 globally with a market cap of $45.38 Billion USD ( CN¥310.15 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #626 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #515 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #536 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $45.98 |
| #600 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $45.38 Billion | CN¥48.62 |
| #626 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €17.90 |
Market Capitalization of Almirall S.A. (2015–2026)
Market capitalization of Almirall S.A. from 2015 to today. Between 2015 and today, Almirall S.A.'s market cap moved from $4.15 Billion to $ 2.64 Billion, with a yearly change of -3.06%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €2.64 Billion | -18.07% |
| 2025 | €3.22 Billion | +55.92% |
| 2024 | €2.07 Billion | -0.70% |
| 2023 | €2.08 Billion | -5.22% |
| 2022 | €2.19 Billion | -18.84% |
| 2021 | €2.70 Billion | +4.56% |
| 2020 | €2.59 Billion | -24.18% |
| 2019 | €3.41 Billion | +10.63% |
| 2018 | €3.08 Billion | +62.28% |
| 2017 | €1.90 Billion | -42.86% |
| 2016 | €3.33 Billion | -19.90% |
| 2015 | €4.15 Billion | -- |
End of Day Market Cap According to Different Sources
On Oct 30th, 2026 the market cap of Almirall S.A. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.63 Billion USD |
| MoneyControl | $2.63 Billion USD |
| MarketWatch | $2.63 Billion USD |
| marketcap.company | $2.63 Billion USD |
| Reuters | $2.63 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Almirall S.A.
Almirall, S.A. operates as a skin health-focused biopharmaceutical company in Spain, Europe, the Middle East, the United States, Asia, and Africa. The company offers its products for skin diseases comprising Psoriasis, atopic dermatitis, acne, actinic keratosis, onychomycosis, androgenic alopecia, oncodermatology, and orphan indications, as well as for alimentary tract and metabolism; antiinfecti… Read more